Cannenta has signed a Heads of Agreement with Tianjin Medis

Continuing to build strategic engagements with value adding organisations around the world, Cannenta has signed a Heads of Agreement with Tianjin Medis for preparation and support in distributing wound care products in the Chinese market.

Tianjin Medis is a successful medical products distribution business operating in China and other countries and has excellent capabilities and existing relationships providing access to very substantial markets for Cannenta products.

They have experience in working with Australian technology ventures and can assist with regulatory approval processes and clinical trials.   Founder and Managing Director, David Zou has also invested in Cannenta and will be joining the board of directors where his commercial skills and experience will contribute to the direction of the business.

Cannenta is a private company in Melbourne Australia developing wound dressing products containing 2-deoxy-D-ribose (2dDR), a compound which has been shown to significantly improve wound bed vascularisation in laboratory and animal trials.   Cannenta will be targeting chronic wound applications including diabetic foot ulcers with a range of wound care products incorporating 2dDR and is finalising preparation to commence clinical trials later in 2023.

The company has an existing agreement with Nexgel Inc (USA) for manufacture of electron-beam hydrogel patches incorporating 2dDR, which will become available for distribution via strategic partners following the clinical program and product registration.

Partnerships with other parties for manufacture of a range of pro-angiogenic wound care products and distribution to global markets are anticipated.

For more information contact:  enquiries@cannenta.com